- Home
- JWSM vs AVIR Comparison
JWSM vs AVIR Comparison
Compare JWSM & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWSM
- AVIR
- Stock Information
- Founded
- JWSM 2020
- AVIR 2012
- Country
- JWSM United States
- AVIR United States
- Employees
- JWSM N/A
- AVIR N/A
- Industry
- JWSM Blank Checks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- JWSM Finance
- AVIR Health Care
- Exchange
- JWSM Nasdaq
- AVIR Nasdaq
- Market Cap
- JWSM 308.5M
- AVIR 290.4M
- IPO Year
- JWSM 2021
- AVIR 2020
- Fundamental
- Price
- JWSM $11.31
- AVIR $3.56
- Analyst Decision
- JWSM
- AVIR Hold
- Analyst Count
- JWSM 0
- AVIR 1
- Target Price
- JWSM N/A
- AVIR $6.88
- AVG Volume (30 Days)
- JWSM 2.7K
- AVIR 152.3K
- Earning Date
- JWSM 01-01-0001
- AVIR 11-06-2024
- Dividend Yield
- JWSM N/A
- AVIR N/A
- EPS Growth
- JWSM N/A
- AVIR N/A
- EPS
- JWSM N/A
- AVIR N/A
- Revenue
- JWSM N/A
- AVIR N/A
- Revenue This Year
- JWSM N/A
- AVIR N/A
- Revenue Next Year
- JWSM N/A
- AVIR N/A
- P/E Ratio
- JWSM N/A
- AVIR N/A
- Revenue Growth
- JWSM N/A
- AVIR N/A
- 52 Week Low
- JWSM $10.50
- AVIR $2.77
- 52 Week High
- JWSM $11.32
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- JWSM 91.47
- AVIR 49.38
- Support Level
- JWSM $11.14
- AVIR $3.31
- Resistance Level
- JWSM $11.32
- AVIR $3.86
- Average True Range (ATR)
- JWSM 0.00
- AVIR 0.12
- MACD
- JWSM -0.00
- AVIR 0.03
- Stochastic Oscillator
- JWSM 50.00
- AVIR 46.90
About JWSM Jaws Mustang Acquisition Corp.
Jaws Mustang Acquisition Corp is a blank check company. it is formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).